Invivyd

Price & Volume

Track all markets on TradingView

Stats

See more
52W Range
$0.35-$4.74
Market Cap
$73.8M
Shares Short
8M

Financials

See more
Revenue (12 Mos)
$25.3M
Revenue Growth (YoY)
0%
Gross Profit (12 Mos)
$23.7M
Diluted EPS
-$1.42

News

See more

Yahoo Finance • 2 days ago

Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

Yahoo Finance • 9 days ago

Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights

Yahoo Finance • 24 days ago

Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Currently Dominant SARS-CoV-2 Variant LP.8.1

Yahoo Finance • last month

FDA Declined Invivyd’s Request to Expand Existing Emergency Use Authorization of PEMGARDA™ (pemivibart) to Include Treatment of Mild-to-Moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options; No Change to the Existing PEMGARDA EUA for Pre-Exposure Prophylaxis of COVID-19 in Certain Immunocompromised Patients

About

CFO
Mr. William E. Duke Jr., M.B.A.
Address
1601 Trapelo Road, Waltham, MA, United States, 02451
Sector
Healthcare
Industry
Biotechnology
Full-Time Employees
99